DK2056874T3 - Tumorterapi med et anti-vegf-antistof - Google Patents

Tumorterapi med et anti-vegf-antistof

Info

Publication number
DK2056874T3
DK2056874T3 DK07786693.7T DK07786693T DK2056874T3 DK 2056874 T3 DK2056874 T3 DK 2056874T3 DK 07786693 T DK07786693 T DK 07786693T DK 2056874 T3 DK2056874 T3 DK 2056874T3
Authority
DK
Denmark
Prior art keywords
vegf antibody
tumor therapy
tumor
therapy
vegf
Prior art date
Application number
DK07786693.7T
Other languages
English (en)
Inventor
Thomas Friess
Max Hasmann
Werner Scheuer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37607207&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2056874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK2056874T3 publication Critical patent/DK2056874T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
DK07786693.7T 2006-08-21 2007-08-17 Tumorterapi med et anti-vegf-antistof DK2056874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06017330 2006-08-21
PCT/EP2007/007276 WO2008022746A1 (en) 2006-08-21 2007-08-17 Tumor therapy with an anti-vegf antibody

Publications (1)

Publication Number Publication Date
DK2056874T3 true DK2056874T3 (da) 2012-10-15

Family

ID=37607207

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07786693.7T DK2056874T3 (da) 2006-08-21 2007-08-17 Tumorterapi med et anti-vegf-antistof

Country Status (29)

Country Link
US (6) US20080050385A1 (da)
EP (2) EP2441472B1 (da)
JP (3) JP2010501498A (da)
KR (1) KR101136763B1 (da)
CN (1) CN101505792B (da)
AR (1) AR062419A1 (da)
AU (1) AU2007287794B2 (da)
BR (1) BRPI0715829A2 (da)
CA (1) CA2660681A1 (da)
CL (1) CL2007002404A1 (da)
CO (1) CO6150193A2 (da)
CR (1) CR10590A (da)
DK (1) DK2056874T3 (da)
ES (2) ES2392630T3 (da)
HK (1) HK1134441A1 (da)
IL (2) IL196810A0 (da)
MA (1) MA30654B1 (da)
MX (1) MX2009001715A (da)
MY (1) MY150756A (da)
NO (1) NO20090450L (da)
NZ (1) NZ574580A (da)
PE (1) PE20080911A1 (da)
PL (1) PL2056874T3 (da)
RU (1) RU2528884C2 (da)
SG (1) SG174090A1 (da)
SI (1) SI2056874T1 (da)
TW (2) TW201107346A (da)
WO (1) WO2008022746A1 (da)
ZA (1) ZA200901200B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL400669A1 (pl) 2000-05-19 2012-11-05 Genentech, Inc. Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka
JP2008507520A (ja) * 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド Ｈｅｒ２抗体組成物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
AU2005314127A1 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a HER inhibitor
KR20190110637A (ko) 2005-01-21 2019-09-30 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
RU2404806C2 (ru) 2005-02-23 2010-11-27 Дженентек, Инк. Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
NZ574580A (en) * 2006-08-21 2011-12-22 Hoffmann La Roche Her2 tumor therapy with an anti-vegf antibody
PE20090681A1 (es) 2007-03-02 2009-06-10 Genentech Inc Prediccion de respuesta a un inhibidor her
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP3539988A3 (en) 2010-05-27 2019-12-04 Genmab A/S Monoclonal antibodies against her2
WO2011147982A2 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
MX339427B (es) * 2010-07-19 2016-05-25 Hoffmann La Roche Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico.
BR112013004012B1 (pt) * 2010-08-20 2021-03-23 Novartis Ag Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN116271013A (zh) 2011-10-14 2023-06-23 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
KR20140094594A (ko) * 2011-12-05 2014-07-30 에프. 호프만-라 로슈 아게 유방암 치료를 위한 베바시주맙 병용 치료에 대한 혈장 바이오마커
WO2013148159A1 (en) * 2012-03-30 2013-10-03 Fibrogen Inc Therapeutic methods for peritoneal carcinomatosis
EP3800204A1 (en) 2013-04-16 2021-04-07 F. Hoffmann-La Roche AG Pertuzumab variants and evaluation thereof
EP3581586A1 (en) 2014-04-25 2019-12-18 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
CN107614015A (zh) 2015-05-30 2018-01-19 豪夫迈·罗氏有限公司 治疗her2阳性局部晚期或先前未治疗的转移性乳腺癌的方法
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
CN106729743B (zh) 2015-11-23 2021-09-21 四川科伦博泰生物医药股份有限公司 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
TW202140776A (zh) * 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
TW201827077A (zh) 2016-12-28 2018-08-01 美商建南德克公司 晚期her2表現癌症之治療
LT3570884T (lt) 2017-01-17 2020-12-10 Genentech, Inc. Poodinės her2 antikūnų kompozicijos
AU2018227788B2 (en) 2017-03-02 2021-04-22 F. Hoffmann-La Roche Ag Adjuvant treatment of HER2-positive breast cancer
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
US20230330094A1 (en) * 2020-09-04 2023-10-19 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Combination compositions and methods for treating cancer

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE348110T1 (de) 1992-10-28 2007-01-15 Genentech Inc Hvegf rezeptor als vegf antagonist
CA2259222A1 (en) 1996-06-27 1997-12-31 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
NZ509480A (en) 1996-10-18 2005-05-27 Genentech Inc Use of anti-ErbB2 antibodies which bind to domain1 of ErbB2 for treating a tumour or cancer
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
KR100794454B1 (ko) 1997-04-07 2008-01-16 제넨테크, 인크. 항-ｖｅｇｆ 항체
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
PL348634A1 (en) 1998-05-15 2002-06-03 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
DE69923849T2 (de) 1998-08-27 2006-01-12 Pfizer Products Inc., Groton Quinolin-2-on-derivate verwendbar als antikrebsmittel
GEP20033001B (en) 1998-08-27 2003-06-25 Pfizer Prod Inc Alkynyl-Substituted Quinolin-2-One Derivatives Useful As Anticancer Agents
ATE384792T1 (de) 1998-11-18 2008-02-15 Genentech Inc Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
HUP0105231A3 (en) 1999-02-11 2003-01-28 Pfizer Prod Inc Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents and medicaments containing the compounds
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
SI1187632T1 (sl) 1999-05-14 2009-04-30 Genentech Inc Zdravljenje z anti-ErbB2 protitelesi
WO2001000238A1 (en) 1999-06-25 2001-01-04 Genentech, Inc. TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
HU226742B1 (en) 1999-06-25 2009-08-28 Genentech Inc Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1456652A4 (en) * 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
AU2003222252A1 (en) 2002-03-12 2003-09-29 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
AU2003224916B2 (en) 2002-04-10 2009-01-08 Genentech, Inc. Anti-HER2 antibody variants
US20040243207A1 (en) 2003-05-30 2004-12-02 Olson Donald R. Medical implant systems
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
WO2005012531A2 (en) 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
JP2008504007A (ja) 2003-12-19 2008-02-14 ジェネンテック・インコーポレーテッド 治療薬として有用な一価抗体断片
WO2006028936A2 (en) * 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
NZ553327A (en) * 2004-10-04 2010-02-26 Genentech Inc Modulators of hepatocyte growth factor activator
BRPI0611766A2 (pt) * 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
TW200812615A (en) * 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
NZ574580A (en) * 2006-08-21 2011-12-22 Hoffmann La Roche Her2 tumor therapy with an anti-vegf antibody
JP2013103182A (ja) * 2011-11-15 2013-05-30 Toray Ind Inc スパイラル型流体分離素子およびその製造方法

Also Published As

Publication number Publication date
CN101505792B (zh) 2012-10-03
BRPI0715829A2 (pt) 2013-07-23
EP2056874B1 (en) 2012-09-19
PE20080911A1 (es) 2008-08-15
US20150239969A1 (en) 2015-08-27
PL2056874T3 (pl) 2013-02-28
ZA200901200B (en) 2013-08-28
US20130183292A1 (en) 2013-07-18
JP2015214582A (ja) 2015-12-03
KR20090032136A (ko) 2009-03-31
AU2007287794B2 (en) 2013-03-28
MX2009001715A (es) 2009-02-25
MA30654B1 (fr) 2009-08-03
AU2007287794A1 (en) 2008-02-28
CN101505792A (zh) 2009-08-12
RU2528884C2 (ru) 2014-09-20
NZ574580A (en) 2011-12-22
US20100285010A1 (en) 2010-11-11
EP2441472B1 (en) 2015-06-10
US20080050385A1 (en) 2008-02-28
IL238045A0 (en) 2015-05-31
CA2660681A1 (en) 2008-02-28
ES2392630T3 (es) 2012-12-12
EP2056874A1 (en) 2009-05-13
NO20090450L (no) 2009-02-27
EP2441472A1 (en) 2012-04-18
RU2009110102A (ru) 2010-09-27
MY150756A (en) 2014-02-28
US20110223159A1 (en) 2011-09-15
HK1134441A1 (en) 2010-04-30
TW200825106A (en) 2008-06-16
CO6150193A2 (es) 2010-04-20
AR062419A1 (es) 2008-11-05
SI2056874T1 (sl) 2012-12-31
JP2013163687A (ja) 2013-08-22
CR10590A (es) 2009-03-20
SG174090A1 (en) 2011-09-29
WO2008022746A1 (en) 2008-02-28
TW201107346A (en) 2011-03-01
US20180251536A1 (en) 2018-09-06
ES2546066T3 (es) 2015-09-18
IL196810A0 (en) 2011-08-01
KR101136763B1 (ko) 2012-04-24
JP2010501498A (ja) 2010-01-21
CL2007002404A1 (es) 2008-04-18

Similar Documents

Publication Publication Date Title
DK2056874T3 (da) Tumorterapi med et anti-vegf-antistof
CY2019004I1 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
LTPA2016005I1 (lt) Anti-il-5 antikūnų skyrimo būdai
CY2018004I2 (el) Συνδυαστικη θεραπεια υποκατεστημενης oξαζολιδινονης
BRPI0819165A2 (pt) Anticorpos anti-vegf
DK2131860T3 (da) Anti-sclerostin-antistoffer
IL205547A0 (en) Anti-vegf antibody compounds and methods
DK2196541T3 (da) Anti-glypican-3-antistof med forbedret kinetik i plasmaet
NO344963B1 (no) Humanisert antistoff
DK1874821T3 (da) Kombination af antistoffer med glykokortikoider til behandling af kræft
CU23869B1 (es) Anticuerpos anti-esclerostina y proteínas funcionales
DK2139987T3 (da) Fremgangsmåder til proteinfremstilling med anti-senescens-forbindelser
DK2066695T3 (da) Anti-myostatin-antistoffer
DK2068874T3 (da) Fremgangsmåder til behandling af multiple myelom med anvendelse af kombinationsterapier baseret på anti-cs1 antistoffer
PL2195026T3 (pl) Przeciwciała przeciw sklerostynie
FI20075278A0 (fi) Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet
DK2035369T3 (da) Terapeutiske
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0909016A2 (pt) anticorpos úteis para o tratamento do câncer
ATE522514T1 (de) Dihydropyran-2-onverbindungen mit antitumorwirkung
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI0818598A2 (pt) agentes terapêuticos - 802
BRPI0807858A2 (pt) Anticorpo de modificação de doença cancerosa
GB0815788D0 (en) Therapeutic antibodies
DE502007001073D1 (de) Gurtaufroller mit kupplungsblockade